Payers eliminated cost-sharing for coronavirus treatment when the pandemic hit the US in March 2020. Now they have the opportunity to use those waivers as a model for reducing low-value care spending and investing in high-value care across the industry. Mark Fendrick, director of the University of Michigan Center for Value-Based Insurance Design and professor of the division of general medicine, department of internal medicine and department of health management and policy at The University of Michigan, shares how payers can make that transition.